Regulatory T cells-an important target for cancer immunotherapy Reply

被引：9

作者：

Drake, Charles G. ^{[1
]}

Lipson, Evan J. ^{[1
]}

Brahmer, Julie R. ^{[1
]}

机构：

[1] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21231 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2014年 / 11卷 / 06期

关键词：

D O I：

10.1038/nrclinonc.2013.208-c2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：307 / 307

页数：1

共 9 条

[1]

[Anonymous], J CLIN ONCOLOGY

[2] Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer [J].

Drake, Charles G. ;

Lipson, Evan J. ;

Brahmer, Julie R. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (01) :24-37

[3] LAG-3 in Cancer Immunotherapy [J].

Goldberg, Monica V. ;

Drake, Charles G. .

CANCER IMMUNOLOGY AND IMMUNOTHERAPY, 2011, 344 :269-278

[4]

Selby M. J., CANC IMMUNOL RES, V1, P32

[5]

Shin J. I., NAT REV CLIN ONCOL

[6] Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma [J].

Simpson, Tyler R. ;

Li, Fubin ;

Montalvo-Ortiz, Welby ;

Sepulveda, Manuel A. ;

Bergerhoff, Katharina ;

Arce, Frederick ;

Roddie, Claire ;

Henry, Jake Y. ;

Yagita, Hideo ;

Wolchok, Jedd D. ;

Peggs, Karl S. ;

Ravetch, Jeffrey V. ;

Allison, James P. ;

Quezada, Sergio A. .

JOURNAL OF EXPERIMENTAL MEDICINE, 2013, 210 (09) :1695-1710

[7]

Sugiyama D., P NATL ACAD SCI US, V110

[8] PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells [J].

Wang, Wenshi ;

Lau, Roy ;

Yu, Daohai ;

Zhu, Weiwei ;

Korman, Alan ;

Weber, Jeffrey .

INTERNATIONAL IMMUNOLOGY, 2009, 21 (09) :1065-1077

[9]

2014, NAT REV CLIN ONCOL, V11, P24

← 1 →